Sukjoong Oh

1.3k total citations
52 papers, 783 citations indexed

About

Sukjoong Oh is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Sukjoong Oh has authored 52 papers receiving a total of 783 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 18 papers in Hematology and 16 papers in Genetics. Recurrent topics in Sukjoong Oh's work include Chronic Lymphocytic Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Lymphoma Diagnosis and Treatment (8 papers). Sukjoong Oh is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Lymphoma Diagnosis and Treatment (8 papers). Sukjoong Oh collaborates with scholars based in South Korea, United States and Thailand. Sukjoong Oh's co-authors include Seoung Wan Chae, Changick Kim, Cheolwon Suh, Dong‐Hoe Koo, Yun‐Gyoo Lee, Yeung‐Chul Mun, Jong-Ho Won, Jung Hye Kwon, Min Kyoung Kim and Seok Jin Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Sukjoong Oh

49 papers receiving 761 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Sukjoong Oh 252 213 164 121 107 52 783
Roos J. Leguit 214 0.8× 209 1.0× 113 0.7× 163 1.3× 158 1.5× 43 887
Tomás Álvaro 618 2.5× 608 2.9× 134 0.8× 190 1.6× 165 1.5× 31 1.5k
Jacob R. Bledsoe 339 1.3× 177 0.8× 206 1.3× 129 1.1× 37 0.3× 47 731
U. Gunzer 147 0.6× 97 0.5× 139 0.8× 61 0.5× 50 0.5× 25 607
Triantafyllia Κoletsa 194 0.8× 131 0.6× 137 0.8× 172 1.4× 61 0.6× 104 844
Paulette Herlin 400 1.6× 143 0.7× 102 0.6× 282 2.3× 71 0.7× 59 1.1k
Dong Soon Lee 267 1.1× 108 0.5× 58 0.4× 393 3.2× 153 1.4× 59 1.0k
Wanming Hu 417 1.7× 82 0.4× 129 0.8× 215 1.8× 158 1.5× 78 944
H Helin 203 0.8× 80 0.4× 170 1.0× 252 2.1× 48 0.4× 35 788
Eric J. Steenbergen 122 0.5× 118 0.6× 52 0.3× 130 1.1× 78 0.7× 21 820

Countries citing papers authored by Sukjoong Oh

Since Specialization
Citations

This map shows the geographic impact of Sukjoong Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sukjoong Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sukjoong Oh more than expected).

Fields of papers citing papers by Sukjoong Oh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sukjoong Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sukjoong Oh. The network helps show where Sukjoong Oh may publish in the future.

Co-authorship network of co-authors of Sukjoong Oh

This figure shows the co-authorship network connecting the top 25 collaborators of Sukjoong Oh. A scholar is included among the top collaborators of Sukjoong Oh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sukjoong Oh. Sukjoong Oh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shin, Dong‐Yeop, Sa-Hee Park, Eun‐Jung Jang, et al.. (2024). Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials. Leukemia Research. 143. 107542–107542. 1 indexed citations
2.
Song, Chang Myeon, et al.. (2024). Comparison of surgical outcomes of transoral robotic and endoscopic thyroidectomy: A systematic review and network meta‐analysis. Head & Neck. 46(3). 688–701. 5 indexed citations
3.
Moon, Kyoung Min, Kyueng‐Whan Min, Woon Yong Jung, et al.. (2023). Low gamma‐butyrobetaine dioxygenase (BBOX1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma: a machine learning approach. The Journal of Pathology Clinical Research. 9(3). 236–248. 2 indexed citations
4.
Lee, Sung‐Eun, Sung-Soo Yoon, Deok‐Hwan Yang, et al.. (2023). A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study. Blood. 142(Supplement 1). 4575–4575. 3 indexed citations
5.
Kang, Ju‐Seop, et al.. (2023). MST1R as a potential new target antigen of chimeric antigen receptor T cells to treat solid tumors. Korean Journal of Physiology and Pharmacology. 27(3). 241–256. 5 indexed citations
6.
Lee, Yoo Jin, Yunsuk Choi, Misung Kim, et al.. (2022). Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma. Journal of Pathology and Translational Medicine. 56(5). 281–288. 2 indexed citations
7.
Lee, Yun‐Gyoo, et al.. (2018). Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer. Supportive Care in Cancer. 27(5). 1945–1949. 11 indexed citations
8.
Min, Kyueng‐Whan, Dong‐Hoon Kim, Byoung Kwan Son, et al.. (2018). High TNFRSF12A level associated with MMP-9 overexpression is linked to poor prognosis in breast cancer: Gene set enrichment analysis and validation in large-scale cohorts. PLoS ONE. 13(8). e0202113–e0202113. 28 indexed citations
9.
Lee, Won-Sik, Hyeoung‐Joon Kim, Jee Hyun Kong, et al.. (2017). Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Blood. 130. 1593–1593. 1 indexed citations
10.
Lee, Yun‐Gyoo, Sukjoong Oh, Heejin Kimm, et al.. (2017). Practice Patterns Regarding Multidisciplinary Cancer Management and Suggestions for Further Refinement: Results from a National Survey in Korea. Cancer Research and Treatment. 49(4). 1164–1169. 8 indexed citations
11.
Min, Kyueng‐Whan, Dong‐Hoon Kim, Dong‐Hoon Kim, et al.. (2016). High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer. Postgraduate Medical Journal. 92(1094). 707–714. 8 indexed citations
12.
Min, Kyueng‐Whan, Seoung Wan Chae, Dong Hoon Kim, et al.. (2015). Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer. Oncology Letters. 10(1). 121–130. 27 indexed citations
13.
Lee, Yun‐Gyoo, Dong‐Hoe Koo, Sukjoong Oh, et al.. (2015). Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. Cancer Chemotherapy and Pharmacology. 76(5). 933–937. 4 indexed citations
14.
Min, Kyueng‐Whan, Dong‐Hoon Kim, Sung‐Im Do, et al.. (2014). Expression patterns of stromal MMP-2 and tumoural MMP-2 and -9 are significant prognostic factors in invasive ductal carcinoma of the breast. Apmis. 122(12). 1196–1206. 37 indexed citations
16.
Kim, Hawk, Kyoo‐Hyung Lee, Sang Kyun Sohn, et al.. (2013). Hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia. Leukemia Research. 37(10). 1241–1247. 4 indexed citations
17.
Choi, Soo-Young, Sung‐Eun Lee, Soo-Hyun Kim, et al.. (2012). Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study. Blood. 120(21). 3775–3775. 2 indexed citations
18.
Koo, Dong‐Hoe, Sang Hyuk Lee, Ki Bae Bang, et al.. (2012). Aggressive Classical Kaposi’s Sarcoma Mimicking Malignant Lymphoma. Pathology & Oncology Research. 18(4). 1067–1069. 1 indexed citations
19.
Goh, Hyun‐Gyung, Saengsuree Jootar, Hyeoung‐Joon Kim, et al.. (2011). Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study). Blood. 118(21). 2765–2765. 12 indexed citations
20.
Baek, Jin Ho, Hawk Kim, Jong‐Joon Ahn, et al.. (2011). Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer. Lung Cancer. 76(3). 368–372. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026